NASDAQ: SLRXSalarius Pharmaceuticals Inc Stock
$0.50-0.06 (-10.71%)
Updated Aug 8, 2025
SLRX Price
$0.50
Fair Value Price
N/A
Market Cap
$1.06M
52 Week Low
$0.45
52 Week High
$7.20
P/E
-0.1x
P/B
17.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.57M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
36.81
Operating Cash Flow
-$4M
Beta
0.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SLRX Overview
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SLRX's potential to beat the market
- SLRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SLRX
RankedUnranked of 478
RankedUnranked of 478
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.30 | A | |
| $11.37 | A | |
| $31.70 | A |
Be the first to know about important SLRX news, forecast changes, insider trades & much more!
SLRX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SLRX is poor value based on its book value relative to its share price (17.19x), compared to the US Biotechnology industry average (4.23x)
P/B vs Industry Valuation
SLRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SLRX due diligence checks available for Premium users.
Valuation
SLRX fair value
Fair Value of SLRX stock based on Discounted Cash Flow (DCF)
Price
$0.50
Fair Value
$2.30
Undervalued by
78.26%
SLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
-248.85x
Market
34.69x
SLRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.19x
Industry
4.23x
SLRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.7M
Profit Margin
0%
SLRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.3M
Liabilities
$2.3M
Debt to equity
36.81
SLRX's short-term assets ($2.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLRX's short-term assets ($2.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
$545.6k
SLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLRX vs Biotech Stocks
Salarius Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.